Artículos de revistas sobre el tema "Doxorubicine – Toxicologie"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Doxorubicine – Toxicologie".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
V., Rakshitha B., Nalini G. K., Sahana G. N., Deepak P., Jayashree V. Nagaral, Mohith N. y Divyashree C. R. "Comparison of safety and toxicity of liposomal versus conventional Doxorubicin: an updated review". International Journal of Basic & Clinical Pharmacology 8, n.º 6 (23 de mayo de 2019): 1453. http://dx.doi.org/10.18203/2319-2003.ijbcp20192220.
Texto completoBressolle, Fran�oise, Jeanne-Marie Jacquet, Marc Galtier, Jacques Jourdan, Daniel Donadio y Jean-Fran�ois Rossi. "Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva". Cancer Chemotherapy and Pharmacology 30, n.º 3 (1992): 215–18. http://dx.doi.org/10.1007/bf00686315.
Texto completoJacquet, Jeanne-Marie, Fran�oise Bressolle, Marc Galtier, Magali Bourrier, Daniel Donadio, Jacques Jourdan y Jean-Fran�ois Rossi. "Doxorubicin and doxorubicinol: intra-and inter-individual variations of pharmacokinetic parameters". Cancer Chemotherapy and Pharmacology 27, n.º 3 (1990): 219–25. http://dx.doi.org/10.1007/bf00685716.
Texto completoCusack, Barry J., Stephan P. Young, Joni Driskell y Richard D. Olson. "Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit". Cancer Chemotherapy and Pharmacology 32, n.º 1 (1993): 53–58. http://dx.doi.org/10.1007/bf00685876.
Texto completoTan, Jun, Jingfen Ye, Meijun Song, Mi Zhou y Yaoren Hu. "Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation". Journal of Biochemical and Molecular Toxicology 32, n.º 1 (7 de noviembre de 2017): e22007. http://dx.doi.org/10.1002/jbt.22007.
Texto completoDuncan, R., J. K. Coatsworth y S. Burtles. "Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymerdoxorubicin (PK1)". Human & Experimental Toxicology 17, n.º 2 (febrero de 1998): 93–104. http://dx.doi.org/10.1177/096032719801700204.
Texto completoDewi, Ermi Girsang, Ali Nafiah Nasution y Liena. "The Effect of Salam Leaf Ethanol Extract on the Histopathology of Doxorubicin-Induced Rats and its Effectiveness in Protecting the Heart Compared with Positive Control (Vitamin E)". International Journal of Science and Environment (IJSE) 1, n.º 1 (21 de noviembre de 2021): 8–14. http://dx.doi.org/10.51601/ijse.v1i1.2.
Texto completoRodrigues, Daniela, Luke Coyle, Barbara Füzi, Sofia Ferreira, Heeseung Jo, Bram Herpers, Seung-Wook Chung et al. "Unravelling Mechanisms of Doxorubicin-Induced Toxicity in 3D Human Intestinal Organoids". International Journal of Molecular Sciences 23, n.º 3 (24 de enero de 2022): 1286. http://dx.doi.org/10.3390/ijms23031286.
Texto completoCandussio, Luigi, Giuliana Decorti, Enrico Crivellato, Marilena Granzotto, Anna Rosati, Tullio Giraldi y Fiora Bartoli. "Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin". Life Sciences 71, n.º 26 (noviembre de 2002): 3109–19. http://dx.doi.org/10.1016/s0024-3205(02)02175-6.
Texto completoChe, Feifei, Yu Liu y Caigang Xu. "Prevention and Treatment of Doxorubicin-Induced Cardiotoxicity by Dexrazoxane and Schisandrin B in Rabbits". International Journal of Toxicology 30, n.º 6 (12 de octubre de 2011): 681–89. http://dx.doi.org/10.1177/1091581811415873.
Texto completoYurtcu, E., ÖD İşeri y FI Sahin. "Genotoxic and cytotoxic effects of doxorubicin and silymarin on human hepatocellular carcinoma cells". Human & Experimental Toxicology 33, n.º 12 (27 de marzo de 2014): 1269–76. http://dx.doi.org/10.1177/0960327114529453.
Texto completoKratz, F., G. Ehling, H.-M. Kauffmann y C. Unger. "Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin". Human & Experimental Toxicology 26, n.º 1 (enero de 2007): 19–35. http://dx.doi.org/10.1177/0960327107073825.
Texto completoMakwana, Vivek, A/Prof Shailendra-Anoopkumar Dukie y Santosh Rudrawar. "Investigating the Impact of OGT Inhibition on Doxorubicin- and Docetaxel-Induced Cytotoxicity in PC-3 and WPMY-1 Cells". International Journal of Toxicology 39, n.º 6 (27 de agosto de 2020): 586–93. http://dx.doi.org/10.1177/1091581820948433.
Texto completoDuncan, R., J. K. Coatsworth y S. Burtles. "Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1)". Human & Experimental Toxicology 17, n.º 2 (1 de febrero de 1998): 93–104. http://dx.doi.org/10.1191/096032798678908378.
Texto completoPoljaková, Jitka, Tomáš Eckschlager, Jana Hřebačková, Jan Hraběta y Marie Stiborová. "The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells". Interdisciplinary Toxicology 1, n.º 2 (1 de septiembre de 2008): 186–89. http://dx.doi.org/10.2478/v10102-010-0036-9.
Texto completoWallace, Kendall B. "Doxorubicin-Induced Cardiac Mitochondrionopathy". Pharmacology & Toxicology 93, n.º 3 (septiembre de 2003): 105–15. http://dx.doi.org/10.1034/j.1600-0773.2003.930301.x.
Texto completoKunarajah, Kuhan, Stefanie Hennig, Ross L. G. Norris, Michael Lobb, Bruce G. Charles, Ross Pinkerton y Andrew S. Moore. "Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?" Cancer Chemotherapy and Pharmacology 80, n.º 1 (25 de abril de 2017): 15–25. http://dx.doi.org/10.1007/s00280-017-3309-6.
Texto completoCallies, Sophie, Dinesh P. de Alwis, James G. Wright, Alan Sandler, Michael Burgess y Leon Aarons. "A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)". Cancer Chemotherapy and Pharmacology 51, n.º 2 (febrero de 2003): 107–18. http://dx.doi.org/10.1007/s00280-002-0542-3.
Texto completoLlesuy, Susana F. y Silvia Lores Arnaiz. "Hepatotoxicity of mitoxantrone and doxorubicin". Toxicology 63, n.º 2 (agosto de 1990): 187–98. http://dx.doi.org/10.1016/0300-483x(90)90042-f.
Texto completoCombs, Alan B. y Daniel Acosta. "Toxic Mechanisms of the Heart: A Review*". Toxicologic Pathology 18, n.º 4a (enero de 1990): 583–96. http://dx.doi.org/10.1177/019262339001804a08.
Texto completoMurugesan Sudha y Thangarasu Vetrichelvan. "Genoprotective effect of D-Pinitol isolated from aerial parts of Soybean plants against Doxorubicin-induced genotoxicity evaluated by in vitro comet assay in Vero cell lines". International Journal of Research in Pharmaceutical Sciences 12, n.º 2 (5 de mayo de 2021): 1379–84. http://dx.doi.org/10.26452/ijrps.v12i2.4694.
Texto completoAn, Jie y M. Saeed Sheikh. "Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity". Current Cancer Drug Targets 19, n.º 5 (24 de abril de 2019): 400–407. http://dx.doi.org/10.2174/1568009618666171129222159.
Texto completoSantos, GC, MR Almeida, LMG Antunes y MLP Bianchi. "Effect of bixin on DNA damage and cell death induced by doxorubicin in HL60 cell line". Human & Experimental Toxicology 35, n.º 12 (11 de julio de 2016): 1319–27. http://dx.doi.org/10.1177/0960327116630352.
Texto completoHong, C. Y., B. N. Chiang, J. Ku y P. Wu. "Screening the in vitro Sperm-immobilizing Effect of some Anticancer Drugs". Human Toxicology 4, n.º 4 (julio de 1985): 461–64. http://dx.doi.org/10.1177/096032718500400412.
Texto completoSatyam, Shakta Mani, Laxminarayana Kurady Bairy, Prakashchandra Shetty, P. Sainath, Sanjay Bharati, Akheruz Zaman Ahmed, Varun Kumar Singh y A. J. Ashwal. "Metformin and Dapagliflozin Attenuate Doxorubicin-Induced Acute Cardiotoxicity in Wistar Rats: An Electrocardiographic, Biochemical, and Histopathological Approach". Cardiovascular Toxicology 23, n.º 2 (febrero de 2023): 107–19. http://dx.doi.org/10.1007/s12012-023-09784-8.
Texto completoZhen, Juan, Haitao Yu, Honglei Ji, Lu Cai, Jiyan Leng y Bradley B. Keller. "Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury". Life Sciences 239 (diciembre de 2019): 117070. http://dx.doi.org/10.1016/j.lfs.2019.117070.
Texto completoMattila, Minttu, Mirva Söderström, Liisa Ailanen, Eriika Savontaus y Mikko Savontaus. "The Effects of Neuropeptide Y Overexpression on the Mouse Model of Doxorubicin-Induced Cardiotoxicity". Cardiovascular Toxicology 20, n.º 3 (6 de diciembre de 2019): 328–38. http://dx.doi.org/10.1007/s12012-019-09557-2.
Texto completoSimon, Deborah L. "Comment: Doxorubicin Extravasations". DICP 23, n.º 11 (noviembre de 1989): 928. http://dx.doi.org/10.1177/106002808902301126.
Texto completoHacker-Klom, Ursula B., Marvin L. Meistrich y Wolfgang Göhde. "Effect of doxorubicin and 4′-epi-doxorubicin on mouse spermatogenesis". Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 160, n.º 1 (marzo de 1986): 39–46. http://dx.doi.org/10.1016/s0027-5107(96)90007-x.
Texto completoH. Abdulrazzaq, Munaf. "Protective Effect of Benfotiamine against Doxorubicin-Induced Cardiotoxicity in Rabbits". Iraqi Journal of Pharmaceutical Sciences ( P-ISSN: 1683 - 3597 , E-ISSN : 2521 - 3512) 16, n.º 1 (31 de marzo de 2017): 14–17. http://dx.doi.org/10.31351/vol16iss1pp14-17.
Texto completoTurdi, Subat, Peisheng Xu, Qun Li, Youqing Shen, Parhat Kerram y Jun Ren. "Amidization of doxorubicin alleviates doxorubicin-induced contractile dysfunction and reduced survival in murine cardiomyocytes". Toxicology Letters 178, n.º 3 (mayo de 2008): 197–201. http://dx.doi.org/10.1016/j.toxlet.2008.03.010.
Texto completoErdogmus Ozgen, Zeynep, Meral Erdinc, İlker Kelle, Levent Erdinc y Yusuf Nergiz. "Protective effects of necrostatin-1 on doxorubicin-induced cardiotoxicity in rat heart". Human & Experimental Toxicology 41 (enero de 2022): 096032712110660. http://dx.doi.org/10.1177/09603271211066066.
Texto completoPowell, S. "Inhibition of doxorubicin-induced membrane damage by thiol compounds: Toxicologic implications of a glutathione-dependent microsomal factor". Free Radical Biology and Medicine 18, n.º 2 (febrero de 1995): 159–68. http://dx.doi.org/10.1016/0891-5849(94)00109-w.
Texto completoTakahashi, Hikari, Hitoshi Tainaka, Masakazu Umezawa, Ken Takeda, Hiromitsu Tanaka, Yoshitake Nishimune y Shigeru Oshio. "Evaluation of testicular toxicology of doxorubicin based on microarray analysis of testicular specific gene expression". Journal of Toxicological Sciences 36, n.º 5 (2011): 559–67. http://dx.doi.org/10.2131/jts.36.559.
Texto completoGołuński, Grzegorz, Agnieszka Borowik, Dariusz Wyrzykowski, Anna Woziwodzka y Jacek Piosik. "Pentoxifylline as a modulator of anticancer drug doxorubicin. Part I: Reduction of doxorubicin DNA binding". Chemico-Biological Interactions 242 (diciembre de 2015): 291–98. http://dx.doi.org/10.1016/j.cbi.2015.10.008.
Texto completoDantas, Danielle, Amanda Gomes Pereira, Anderson Seiji Soares Fujimori, Ana Paula Dantas Ribeiro, Carol Cristina Vágula de Almeida Silva, Marina Gaiato Monte, Camila Renata Corrêa et al. "Doxycycline Attenuates Doxorubicin-Induced Cardiotoxicity by Improving Myocardial Energy Metabolism in Rats". Journal of Cardiovascular Development and Disease 9, n.º 8 (8 de agosto de 2022): 254. http://dx.doi.org/10.3390/jcdd9080254.
Texto completoBast, A., H. Kaiserová, G. J. M. Hartog, G. R. M. M. Haenen y W. J. F. Vijgh1. "Protectors against doxorubicin-induced cardiotoxicity: Flavonoids". Cell Biology and Toxicology 23, n.º 1 (24 de octubre de 2006): 39–47. http://dx.doi.org/10.1007/s10565-006-0139-4.
Texto completoAlGhamdi, S., V. Leoncikas, K. E. Plant y N. J. Plant. "Synergistic interaction between lipid-loading and doxorubicin exposure in Huh7 hepatoma cells results in enhanced cytotoxicity and cellular oxidative stress: implications for acute and chronic care of obese cancer patients". Toxicology Research 4, n.º 6 (2015): 1479–87. http://dx.doi.org/10.1039/c5tx00173k.
Texto completoKoleini, Navid, Barbara E. Nickel, Andrea L. Edel, Robert R. Fandrich, Amir Ravandi y Elissavet Kardami. "Oxidized phospholipids in Doxorubicin-induced cardiotoxicity". Chemico-Biological Interactions 303 (abril de 2019): 35–39. http://dx.doi.org/10.1016/j.cbi.2019.01.032.
Texto completoTao, Zhimin, Henry G. Withers, Harvey S. Penefsky, Jerry Goodisman y Abdul-Kader Souid. "Inhibition of Cellular Respiration by Doxorubicin". Chemical Research in Toxicology 19, n.º 8 (agosto de 2006): 1051–58. http://dx.doi.org/10.1021/tx050315y.
Texto completoMohan, Uma Priya, Tirupathi Pichiah P.B., Syeda Thabassum Akhtar Iqbal y Sankarganesh Arunachalam. "Mechanisms of doxorubicin-mediated reproductive toxicity – A review". Reproductive Toxicology 102 (junio de 2021): 80–89. http://dx.doi.org/10.1016/j.reprotox.2021.04.003.
Texto completoDesai, Varsha G., Vikrant Vijay, Tao Han, Carrie L. Moland, Bounleut Phanavanh, Taewon Lee, Kelly J. Davis, Levan Muskhelishvili, Kimo C. Stine y James C. Fuscoe. "Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice". Journal of Applied Toxicology 42, n.º 5 (20 de octubre de 2021): 778–92. http://dx.doi.org/10.1002/jat.4256.
Texto completoBar-Joseph, Hadas, Irit Ben-Aharon, Shulamith Rizel, Salomon M. Stemmer, Moran Tzabari y Ruth Shalgi. "Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes☆". Reproductive Toxicology 30, n.º 4 (diciembre de 2010): 566–72. http://dx.doi.org/10.1016/j.reprotox.2010.07.003.
Texto completoGunv�n, Peter, Nils Olof Theve y Curt Peterson. "Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer". Cancer Chemotherapy and Pharmacology 17, n.º 2 (junio de 1986): 153–56. http://dx.doi.org/10.1007/bf00306745.
Texto completoYourtee, David M., Linda L. Elkins, Elisabet L. Nalvarte y Robert E. Smith. "Amplification of doxorubicin mutagenicity by cupric ion". Toxicology and Applied Pharmacology 116, n.º 1 (septiembre de 1992): 57–65. http://dx.doi.org/10.1016/0041-008x(92)90144-h.
Texto completoAkinjo, Oluwajoba O., Timothy W. Gant y Emma L. Marczylo. "Perturbation of microRNA signalling by doxorubicin in spermatogonial, Leydig and Sertoli cell lines in vitro". Toxicology Research 7, n.º 5 (2018): 760–70. http://dx.doi.org/10.1039/c7tx00314e.
Texto completoChurch, Rachel J., J. Eric McDuffie, Manisha Sonee, Monicah Otieno, Jing Ying Ma, Xuejun Liu, Paul B. Watkins y Alison H. Harrill. "MicroRNA-34c-3p is an early predictive biomarker for doxorubicin-induced glomerular injury progression in male Sprague-Dawley rats". Toxicol. Res. 3, n.º 5 (2014): 384–94. http://dx.doi.org/10.1039/c4tx00051j.
Texto completoAkinjo, Oluwajoba O., Timothy W. Gant y Emma L. Marczylo. "Perturbation of epigenetic processes by doxorubicin in the mouse testis". Toxicology Research 5, n.º 4 (2016): 1229–43. http://dx.doi.org/10.1039/c6tx00078a.
Texto completoKlimtová, Ivona, Tomáš Šimůnek, Yvona Mazurová, Radomír Hrdina, Vladimír Gerš y Michaela Adamcová. "Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits". Human & Experimental Toxicology 21, n.º 12 (diciembre de 2002): 649–57. http://dx.doi.org/10.1191/0960327102ht311oa.
Texto completoHu, B., H. Tan, L. Yu, Q. Liao y W. Guo. "Repurposing Ivermectin to augment chemotherapy’s efficacy in osteosarcoma". Human & Experimental Toxicology 41 (enero de 2022): 096032712211436. http://dx.doi.org/10.1177/09603271221143693.
Texto completo